Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BiomX ( (PHGE) ) has issued an update.
On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b clinical trial for BX004, a treatment for Cystic Fibrosis associated with chronic Pseudomonas aeruginosa infections, due to resource constraints. The company is now focusing on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, while also implementing cost-cutting measures and exploring strategic alternatives.
The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing bacteriophage-based therapeutics. The company targets conditions such as Cystic Fibrosis and diabetic foot infections, with a market focus on innovative treatments for bacterial infections.
Average Trading Volume: 52,656
Technical Sentiment Signal: Sell
Current Market Cap: $7.89M
For detailed information about PHGE stock, go to TipRanks’ Stock Analysis page.